Shots: uniQure to receive $2B+ including $450M as up front in cash, $1.6B as regulatory & commercial milestones along with royalties in sales of AMT-061 (etranacogene dezaparvovec) while CSL Behring to get an exclusive global right to commercialize AMT-061 uniQure will be responsible for the completion of the P-III HOPE-B study and scale-up manufacture for […]Read More
Shots: uniQure has an option to acquire Gen-X to identify novel synthetic promoters to be use in gene therapy products, until the expiry of research collaboration The companies will exclusively work together to develop promoters utilizing SuRE technology for the uniQure’s research pipeline and will explore the further development of AAV vector libraries containing fragments […]Read More
Shots: The FDA’s FT designation follows P-I/II study assessing AMT-130 in patients with Huntington’s disease with an expected initiation in H2’19 FDA grant Fast Track designation to facilitate the development & and expedite the review of drugs to treat serious conditions and fill an unmet medical need AMT-130 is an AVV5 gene therapy one-time administered […]Read More
Copyright ©2021 PharmaShots | Powered by Octavus Consulting
